Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
OBJECTIVE
The specific goal of this retrospective study is to evaluate the role of total skin electron beam therapy (TSEBT) in the treatment of Mycosis Fungoides (MF) and to assess the most significant prognostic factors in univariate and multivariate analyses.


METHODS
From January 1985 to December 1999, 92 TSEBT (Stanford Standing technique) were performed on a total of 86 patients (63 with Mycosis Fungoides, 6 with Sezary Syndrome and 17 with Cutaneous Lymphomas). This study considers only the Mycosis Fungoides group, which consisted of 60 cases evaluable for response, survival and toxicity. The distribution of patients by stage (MFCG Staging Classification, 1991) was 21, 5, 12, 22 for stages I, II, III and IV, respectively.


RESULTS
The overall response rate was 96.6% (58/60) with complete response (CR) in 50/60 patients (83.3%) and partial response (PR) in 8 cases (13.3%). The five-year and ten-year actuarial overall survival (OS) was 50% and 45%, respectively. Local control, intended as control of the disease in the skin, was 35% at five years and 20% at ten years, and was correlated with skin involvement. The prognostic factors confirmed by the multivariate analysis for both overall survival and local control were: T (p<0.001) and response after TSEBT (p<0.001). The treatment was very well tolerated.


CONCLUSIONS
Our study showed good results in terms of response and survival with a long follow-up time (mean value 40 months). We confirm that TSEBT yields very good results in early-stage MF; additional trials of combined modality and investigational therapies are needed to improve the outcome for advanced-stage disease.
Rampino
Monica
M
Dipartimento di Radioterapia, Università degli Studi, Turin, Italy.
Ragona
Riccardo
R
Monetti
Ugo
U
Mussano
Anna
A
Guarneri
Alessia
A
Sannazzari
Gian Luca
GL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004583:Electrons; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000401:mortality / Q000532:radiotherapy*; D011379:Prognosis; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000532:radiotherapy; D012878:Skin Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate